(IN BRIEF) Boehringer Ingelheim has reported encouraging Phase II trial results for apecotrep (BI 764198), a potential first-in-class oral TRPC6 inhibitor being developed for primary focal segmental glomerulosclerosis. Published in The Lancet, the study showed a 40% reduction in proteinuria … Read the full press release →
Posted in Germany, Healthcare, Management, News, Pharma & Biotech, Science
Tagged apecotrep BI 764198, Boehringer Ingelheim, Boehringer Ingelheim Advances Targeted Kidney Disease Pipeline with Promising Phase II Data for Apecotrep in FSGS, FSGS, Howard Trachtman, kidney disease research, non immunosuppressive therapy, Paola Casarosa, Phase II clinical trial, Phase III clinical development, podocyte protection, primary focal segmental glomerulosclerosis, proteinuria reduction, rare kidney diseases, renal disease innovation, TRPC6 inhibitor
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Load more...
